Balyasny Asset Management LLC Neurocrine Biosciences Inc Transaction History

Balyasny Asset Management LLC

$58 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $26.5 Million - $29.2 Million	-203,142 Reduced 92.41%	16,684 $2.3 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $27.4 Million - $34.3 Million	-258,262 Reduced 54.02%	219,826 $29 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $27.9 Million - $34.8 Million	-296,976 Reduced 38.32%	478,088 $53.8 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $69.4 Million - $81.3 Million	775,064 New	775,064 $73.1 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $23.3 Million - $30.5 Million	-321,388 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $12.9 Million - $17.2 Million	162,064 Added 101.72%	321,388 $27.4 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $13.7 Million - $15.8 Million	159,324 New	159,324 $15.3 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $274,632 - $385,988	-2,856 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $243,017 - $372,308	2,856 New	2,856 $348,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $8.92 Million - $12.2 Million	-102,759 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $8.61 Million - $10.4 Million	102,759 New	102,759 $9.26 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $7.18 Million - $9.07 Million	-99,366 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $6.89 Million - $9.09 Million	99,366 New	99,366 $8.75 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $11.2 Million - $20.4 Million	-163,917 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $5.34 Million - $6.79 Million	-53,965 Reduced 24.77%	163,917 $20.2 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $1.2 Million - $1.69 Million	-15,934 Reduced 6.81%	217,882 $21.4 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $9.73 Million - $11.9 Million	-128,233 Reduced 35.42%	233,816 $19.4 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $14.1 Million - $18.7 Million	-240,633 Reduced 39.93%	362,049 $28.1 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $28.9 Million - $36.9 Million	602,682	602,682 $36.9 Million

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.77 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.25 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$644 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$322 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$233 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account